|Title||PharmAbcine is invited and will attend to the 35th Annual J.P. Morgan Healthcare Conference.|
PharmAbcine is invited and will attend to the 35th Annual J.P. Morgan Healthcare Conference
Daejeon, South Korea., Jan. 06, 2017 -- PharmAbcine, a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Jin-San Yoo., Ph.D., President and Chief Executive Officer, will attend to the 35th Annual J.P. Morgan Healthcare Conference and present PharmAbcine’s R&D progress at the prearranged meetings with partners.
PharmAbcine, Inc. discovers and develops innovative bio-therapeutics to improve the quality of patients’ life with devastating diseases like cancer and auto immune diseases. PharmAbcine`s competitive fully human antibody libraries, target customized selection system for druggable candidate, innovative multispecific antibody platforms, patients derived cancer stem cell collections under the collaboration with Samsung medical Center and its animal model systemto validate drug candidates, innovative pipeline and established 3G System to generate high performing cell line system will position PharmAbcine as a leading immuno-oncology company.
The ongoing strategic collaborations with leading both global and domestic pharmaceutical companies look promising product candidates in clinical and nonclinical development stage.
For more information, please visit www.pharmabcine.com.
Dr. Sung Woo Kim, Investor Relations